Bimodal Release Two-In-One Clonazepam Matrix Lozenge Tablets for Managing Anxiety-Related Disorders: Formulation, Optimization and In Vivo Evaluation

Clonazepam (CLZ), an antipsychotic drug reported for its efficiency in managing anxiety-related disorders, is being marketed only as conventional tablets. Some patients have abstention to swallow the conventional tablets; therefore, the proposed study was aimed at developing a buccal lozenge tablet...

Full description

Saved in:
Bibliographic Details
Main Authors: Eman Gomaa (Author), Sami El Deeb (Author), Adel Ehab Ibrahim (Author), Mennatullah M. Faisal (Author)
Format: Book
Published: MDPI AG, 2022-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_148d2b3027d64198ab2166f565568cd9
042 |a dc 
100 1 0 |a Eman Gomaa  |e author 
700 1 0 |a Sami El Deeb  |e author 
700 1 0 |a Adel Ehab Ibrahim  |e author 
700 1 0 |a Mennatullah M. Faisal  |e author 
245 0 0 |a Bimodal Release Two-In-One Clonazepam Matrix Lozenge Tablets for Managing Anxiety-Related Disorders: Formulation, Optimization and In Vivo Evaluation 
260 |b MDPI AG,   |c 2022-07-01T00:00:00Z. 
500 |a 10.3390/scipharm90030043 
500 |a 2218-0532 
500 |a 0036-8709 
520 |a Clonazepam (CLZ), an antipsychotic drug reported for its efficiency in managing anxiety-related disorders, is being marketed only as conventional tablets. Some patients have abstention to swallow the conventional tablets; therefore, the proposed study was aimed at developing a buccal lozenge tablet by direct compression of two types of optimized granules. Conazepam's water solubility was first enhanced by a solid dispersion technique for a fast and better dissolution of type 1 granules, while the impact of gelling polymers was investigated on controlled-release type 2 granules. The optimized formulae met the acceptable pharmacopeial limits for tablets' evaluation. A differential scanning calorimetry study revealed the compatibility between the drug and used excipients. All formulae gave a burst release of CLZ in the first hour of investigation, followed by a sustained release over 24 h. The formula that showed the highest prolonged in vitro release (99.0 + 0.1%), following the Higuchi diffusion model (R<sup>2</sup> = 0.99), was then selected for further study. The formula succeeded in controlling the induced stress in a rat model with a significant impact on the behavioral tests throughout the experiment. The results were further confirmed by a pharmacokinetic study that showed a significant increase in Cmax, Tmax, and AUC (1.5, 2, and 3.9 folds), respectively, compared to oral suspension. The newly proposed delivery system has proven a better efficacy with a reduced dosing frequency. 
546 |a EN 
690 |a Clonazepam 
690 |a buccal lozenge tablets 
690 |a bimodal behavior 
690 |a pharmacokinetic 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Scientia Pharmaceutica, Vol 90, Iss 3, p 43 (2022) 
787 0 |n https://www.mdpi.com/2218-0532/90/3/43 
787 0 |n https://doaj.org/toc/0036-8709 
787 0 |n https://doaj.org/toc/2218-0532 
856 4 1 |u https://doaj.org/article/148d2b3027d64198ab2166f565568cd9  |z Connect to this object online.